Theravance Biopharma, Inc. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
Theravance Biopharma, Inc. (TBPH) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $5.99 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Shareholders' Equity
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-11
- Theravance Biopharma, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $5.99M, a 31.85% increase year-over-year.
- Theravance Biopharma, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $4.50M, a 7.65% decline year-over-year.
- Theravance Biopharma, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-12-31 was $4.48M, a 23.10% decline year-over-year.
- Theravance Biopharma, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $4.58M, a 7.80% decline year-over-year.
- Theravance Biopharma, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $18.48M, a 13.64% decline from fiscal 2024.
- Theravance Biopharma, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $21.39M, a 15.68% decline from fiscal 2023.
- Theravance Biopharma, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $25.37M, a 36.15% decline from fiscal 2022.
- Theravance Biopharma, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $39.73M, a 35.98% decline from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2026-06-30 | $5.99M 10-Q · filed 2026-08-11 | $10.49M 10-Q · filed 2026-08-11 | $14.97M derived: sum of 3 quarters · filed 2026-08-11 | $19.55M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $4.50M 10-Q · filed 2026-05-07 | $8.98M derived: sum of 2 quarters · filed 2026-05-07 | $13.56M derived: sum of 3 quarters · filed 2026-05-07 | $18.10M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $4.48M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | $9.06M derived: sum of 2 quarters · filed 2026-03-23 | $13.60M derived: sum of 3 quarters · filed 2026-08-11 | $18.48M 10-K · filed 2026-03-23 |
| 2025-09-30 | $4.58M 10-Q · filed 2025-11-12 | $9.12M derived: sum of 2 quarters · filed 2026-08-11 | $14.00M 10-Q · filed 2025-11-12 | $19.82M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $4.54M 10-Q · filed 2026-08-11 | $9.42M 10-Q · filed 2026-08-11 | $15.25M derived: sum of 3 quarters · filed 2026-08-11 | $20.21M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $4.88M 10-Q · filed 2026-05-07 | $10.70M derived: sum of 2 quarters · filed 2026-05-07 | $15.67M derived: sum of 3 quarters · filed 2026-05-07 | $21.04M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $5.83M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | $10.79M derived: sum of 2 quarters · filed 2026-03-23 | $16.16M derived: sum of 3 quarters · filed 2026-03-23 | $21.39M 10-K · filed 2026-03-23 |
| 2024-09-30 | $4.96M 10-Q · filed 2025-11-12 | $10.34M derived: sum of 2 quarters · filed 2025-11-12 | $15.57M 10-Q · filed 2025-11-12 | $21.39M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $5.38M 10-Q · filed 2025-08-13 | $10.60M 10-Q · filed 2025-08-13 | $16.43M derived: sum of 3 quarters · filed 2025-08-13 | $22.69M derived: sum of 4 quarters · filed 2025-08-13 |
| 2024-03-31 | $5.23M 10-Q · filed 2025-05-12 | $11.05M derived: sum of 2 quarters · filed 2025-05-12 | $17.32M derived: sum of 3 quarters · filed 2025-05-12 | $23.58M derived: sum of 4 quarters · filed 2025-05-12 |
| 2023-12-31 | $5.82M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-07 | $12.09M derived: sum of 2 quarters · filed 2025-03-07 | $18.35M derived: sum of 3 quarters · filed 2025-03-07 | $25.37M 10-K · filed 2025-03-07 |
| 2023-09-30 | $6.26M 10-Q · filed 2024-11-14 | $12.53M derived: sum of 2 quarters · filed 2024-11-14 | $19.55M 10-Q · filed 2024-11-14 | $26.50M derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | $6.26M 10-Q · filed 2024-08-08 | $13.29M 10-Q · filed 2024-08-08 | $20.23M derived: sum of 3 quarters · filed 2024-08-08 | $28.77M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $7.02M 10-Q · filed 2024-05-15 | $13.97M derived: sum of 2 quarters · filed 2024-05-15 | $22.50M derived: sum of 3 quarters · filed 2024-05-15 | $32.21M derived: sum of 4 quarters · filed 2024-05-15 |
| 2022-12-31 | $6.95M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-01 | $15.48M derived: sum of 2 quarters · filed 2024-03-01 | $25.19M derived: sum of 3 quarters · filed 2024-03-01 | $39.73M 10-K · filed 2024-03-01 |
| 2022-09-30 | $8.53M 10-Q · filed 2023-11-09 | $18.24M derived: sum of 2 quarters · filed 2023-11-09 | $32.78M 10-Q · filed 2023-11-09 | $49.70M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $9.71M 10-Q · filed 2023-08-09 | $24.25M 10-Q · filed 2023-08-09 | $41.17M derived: sum of 3 quarters · filed 2023-08-09 | $55.54M derived: sum of 4 quarters · filed 2023-08-09 |
| 2022-03-31 | $14.54M 10-Q · filed 2023-05-10 | $31.46M derived: sum of 2 quarters · filed 2023-05-10 | $45.83M derived: sum of 3 quarters · filed 2023-05-10 | $60.77M derived: sum of 4 quarters · filed 2023-05-10 |
| 2021-12-31 | $16.92M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | $31.29M derived: sum of 2 quarters · filed 2023-03-01 | $46.23M derived: sum of 3 quarters · filed 2023-03-01 | $62.06M 10-K · filed 2023-03-01 |
| 2021-09-30 | $14.37M 10-Q · filed 2022-11-09 | $29.31M derived: sum of 2 quarters · filed 2022-11-09 | $45.14M 10-Q · filed 2022-11-09 | $60.69M derived: sum of 4 quarters · filed 2023-03-01 |
| 2021-06-30 | $14.94M 10-Q · filed 2022-08-08 | $30.77M 10-Q · filed 2022-08-08 | $46.32M derived: sum of 3 quarters · filed 2023-03-01 | $61.89M derived: sum of 4 quarters · filed 2023-03-01 |
| 2021-03-31 | $15.83M 10-Q · filed 2022-05-06 | $31.38M derived: sum of 2 quarters · filed 2023-03-01 | $46.95M derived: sum of 3 quarters · filed 2023-03-01 | $63.53M derived: sum of 4 quarters · filed 2023-03-01 |
| 2020-12-31 | $15.55M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | $31.11M derived: sum of 2 quarters · filed 2023-03-01 | $47.70M derived: sum of 3 quarters · filed 2023-03-01 | $62.98M 10-K · filed 2023-03-01 |
| 2020-09-30 | $15.56M 10-Q · filed 2021-11-08 | $32.15M derived: sum of 2 quarters · filed 2021-11-08 | $47.42M 10-Q · filed 2021-11-08 | $71.34M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-06-30 | $16.59M 10-Q · filed 2021-08-05 | $31.86M 10-Q · filed 2021-08-05 | $55.77M derived: sum of 3 quarters · filed 2022-02-28 | $68.79M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-03-31 | $15.28M 10-Q · filed 2021-05-06 | $39.19M derived: sum of 2 quarters · filed 2022-02-28 | $52.21M derived: sum of 3 quarters · filed 2022-02-28 | $63.51M derived: sum of 4 quarters · filed 2022-02-28 |
| 2019-12-31 | $23.91M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $36.93M derived: sum of 2 quarters · filed 2022-02-28 | $48.23M derived: sum of 3 quarters · filed 2022-02-28 | $60.45M 10-K · filed 2022-02-28 |
| 2019-09-30 | $13.02M 10-Q · filed 2020-11-09 | $24.32M derived: sum of 2 quarters · filed 2020-11-09 | $36.54M 10-Q · filed 2020-11-09 | $48.25M derived: sum of 4 quarters · filed 2021-02-26 |
| 2019-06-30 | $11.30M 10-Q · filed 2020-08-10 | $23.52M 10-Q · filed 2020-08-10 | $35.23M derived: sum of 3 quarters · filed 2021-02-26 | $46.96M derived: sum of 4 quarters · filed 2021-02-26 |
| 2019-03-31 | $12.22M 10-Q · filed 2020-05-08 | $23.93M derived: sum of 2 quarters · filed 2021-02-26 | $35.66M derived: sum of 3 quarters · filed 2021-02-26 | $49.53M derived: sum of 4 quarters · filed 2021-02-26 |
| 2018-12-31 | $11.71M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-26 | $23.44M derived: sum of 2 quarters · filed 2021-02-26 | $37.31M derived: sum of 3 quarters · filed 2021-02-26 | $51.31M 10-K · filed 2021-02-26 |
| 2018-09-30 | $11.73M 10-Q · filed 2019-11-08 | $25.60M derived: sum of 2 quarters · filed 2019-11-08 | $39.60M 10-Q · filed 2019-11-08 | |
| 2018-06-30 | $13.87M 10-Q · filed 2019-08-05 | $27.87M 10-Q · filed 2019-08-05 | ||
| 2018-03-31 | $14.00M 10-Q · filed 2019-05-10 | |||
| 2017-12-31 | $49.17M 10-K · filed 2020-02-27 | |||
| 2016-12-31 | $41.29M 10-K · filed 2019-02-28 | |||
| 2015-12-31 | $54.17M 10-K · filed 2018-02-28 | |||
| 2014-12-31 | $43.45M 10-K · filed 2017-03-01 | |||
| 2013-12-31 | $22.65M 10-K · filed 2016-03-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |